Nattokinase for Circulation

Your blood never stops moving — and when it slows down, the consequences range from cold hands and fatigue to serious cardiovascular events affecting more than 230 million people worldwide.

Poor circulation is one of the most common yet underappreciated factors in long-term vascular health. Nattokinase — a fibrinolytic enzyme derived from fermented soybeans — has attracted research interest for its ability to support blood flow through several complementary pathways. This article examines what the science actually shows, where evidence is strong, and where it is still developing.

Table of Contents

1. Why Circulation Matters — and When It Goes Wrong
2. How Nattokinase Supports Blood Flow: The Mechanisms
3. Human Evidence: What Clinical Studies Show
4. Nattokinase and Microcirculation: The Overlooked Piece
5. Realistic Expectations: What Nattokinase Is and Is Not
6. Who May Benefit — and Who Should Be Cautious
7. BioAbsorb Nattokinase: Formulated for Enzyme Delivery
8. Frequently Asked Questions
9. Conclusion

Why Circulation Matters — and When It Goes Wrong

Every cell in the body depends on adequate blood flow to receive oxygen and nutrients and to remove waste. The circulatory system accomplishes this through a network of arteries, capillaries, and veins — each with a specific role. When flow slows, narrows, or becomes obstructed at any level of this network, tissues downstream feel the effects.

Peripheral artery disease (PAD) — characterised by arterial narrowing from plaque accumulation — affects an estimated 200 million adults worldwide, with US prevalence around 7%, or approximately 8.5 million people. Prevalence rises sharply with age, exceeding 15% in individuals aged 70 and older. Notably, up to half of those with PAD may have no symptoms, making the condition frequently undetected until it is more advanced.

Beyond structural arterial disease, circulation quality is also affected by factors such as elevated blood viscosity, excessive red blood cell clumping (aggregation), fibrin accumulation in vessel walls, and platelet hyperactivity. These subtler changes impair flow at the microvascular level — in the smallest capillaries where exchange of oxygen and nutrients actually occurs — even when larger arteries remain clear. Understanding this distinction is relevant to how nattokinase may support vascular function.

How Nattokinase Supports Blood Flow: The Mechanisms

Nattokinase is a serine protease enzyme — meaning it cleaves protein bonds — extracted from Bacillus subtilis fermentation of soybeans. Its relevance to circulation stems from its action on fibrin, the structural protein that forms blood clots and, when present in excess, contributes to reduced vascular patency. Unlike the body's primary fibrinolytic enzyme, plasmin, nattokinase does not require prior activation: it works directly on already-formed clots.

Research has identified four main pathways through which nattokinase supports fibrinolysis and blood flow:

• Direct fibrin cleavage — Nattokinase dissolves fibrin by hydrolysing peptide bonds at lysine and arginine residues, breaking cross-linked clots into soluble degradation products. In laboratory models, this cleavage was found to be six times more efficient than plasmin in kinetic terms.
• PAI-1 inactivation — Plasminogen activator inhibitor-1 (PAI-1) is the primary brake on the body's own clot-dissolving system. Nattokinase cleaves and inactivates PAI-1, allowing tissue plasminogen activator (tPA) to function more freely, amplifying the body's endogenous fibrinolytic response.
• tPA upregulation — Beyond removing the PAI-1 brake, nattokinase stimulates the release of tPA from vascular endothelial cells, further enhancing natural fibrinolytic capacity through a dual mechanism.
• Platelet aggregation inhibition — A 2013 study found nattokinase significantly inhibited both collagen- and thrombin-induced platelet aggregation and reduced thromboxane B2 formation in a dose-dependent manner — effects relevant to preventing the platelet clumping that precedes arterial occlusion.

Together, these pathways address circulation not just by dissolving existing fibrin but by shifting the overall coagulation/fibrinolysis balance toward a more flow-supportive state. This multi-mechanism profile distinguishes nattokinase from single-pathway anticoagulants and is a key reason for sustained research interest in the enzyme. For a full walkthrough of nattokinase's fibrinolytic cascade, see how nattokinase works.

Human Evidence: What Clinical Studies Show

The human evidence for nattokinase's circulatory effects spans several study designs. The most directly relevant to blood flow used measurable biomarkers and functional endpoints in controlled settings. (See the complete nattokinase guide for background on the enzyme itself.)

A 2015 double-blind, placebo-controlled crossover study in 12 healthy males administered a single 2,000 FU dose of nattokinase and measured coagulation and fibrinolysis parameters at 2, 4, 6, and 8 hours post-dose. The results showed that D-dimer concentrations rose significantly at 6 and 8 hours, and fibrin/fibrinogen degradation products elevated at 4 hours — confirming active fibrinolysis in living humans following a single oral dose.

A Japanese randomised crossover trial (Watanabe et al., 2018) examined peripheral blood flow directly. A single 2,000 FU dose of nattokinase enhanced measured skin blood flow in the fingers of healthy participants compared to placebo, providing human evidence of improved peripheral circulation at the standard supplemental dose.

A 2023 double-blind, placebo-controlled crossover study extended this finding, examining whether nattokinase affected skin temperature recovery after cold water immersion — a functional proxy for peripheral circulation. The study found a statistically significant treatment effect on skin temperature in the middle finger, palm, and back of the right hand (p < 0.05) following a single 2,000 FU dose, supporting improved microvascular responsiveness.

The USC-led Nattokinase Atherothrombotic Prevention Study (NAPS) — a larger double-blind RCT with 265 participants at median age 65.3 years — assessed nattokinase's effect on subclinical atherosclerosis markers including carotid intima-media thickness (CIMT) and arterial stiffness over several years. While outcomes on atherosclerosis progression were modest, the trial confirmed the safety profile and provided the most rigorous long-term human dataset available to date for cardiovascular nattokinase research.

It is worth noting that most human trials feature relatively small sample sizes (under 100 participants) and short intervention periods. The evidence base is promising and mechanistically coherent, but large-scale Phase III RCTs with clinical endpoints — hospitalisation, cardiovascular events — have not yet been completed. Expectations should be calibrated accordingly.

Nattokinase and Microcirculation: The Overlooked Piece

Much of the conversation around nattokinase focuses on large-vessel outcomes — arterial clots, blood pressure, carotid wall thickness. But some of the most relevant work concerns microcirculation: the network of capillaries and arterioles where oxygen exchange actually happens at the tissue level.

A research team at the USC Keck School of Medicine studied nattokinase's effect on red blood cell (RBC) aggregation and whole blood viscosity in vitro — two variables with direct implications for microvascular flow. Blood samples incubated with nattokinase showed a significant, dose-dependent decrease in RBC aggregation and low-shear blood viscosity. Crucially, these benefits appeared at concentrations comparable to those achieved in prior animal trials — suggesting the in vitro findings reflect what may occur physiologically.

Why does this matter? Capillary diameter often equals or is smaller than a single red blood cell. When RBCs clump together or blood becomes thicker at low shear rates, they cannot navigate the smallest vessels efficiently. This leads to sluggish microcirculation, inadequate oxygen delivery to peripheral tissues, and over time, impaired endothelial function. Elevated whole blood viscosity is itself recognised as an independent risk factor for cardiovascular events.

Nattokinase's ability to reduce RBC aggregation and low-shear viscosity suggests a mechanism of action beyond large-clot dissolution — one that could support everyday circulation quality in tissues most dependent on fine vascular networks: fingers, toes, retinal vasculature, and peripheral extremities. This is an area where further human trial data would be valuable; current evidence remains primarily in vitro and animal.

Realistic Expectations: What Nattokinase Is and Is Not

Nattokinase is a well-characterised fibrinolytic enzyme with a growing body of evidence supporting its circulatory mechanisms. It is not a pharmaceutical anticoagulant, and it should not be framed as a replacement for medications prescribed to manage established cardiovascular disease. Understanding this distinction is important for making informed decisions about supplementation.

What the evidence supports:

• Measurable fibrinolytic activity in healthy human subjects following a single oral dose
• Inhibition of platelet aggregation and thrombus formation in animal models and in vitro
• Reduction in RBC aggregation and blood viscosity in vitro at physiologically relevant concentrations
• Improved peripheral blood flow signals in small human trials (finger blood flow, skin temperature recovery)
• A well-established multi-pathway mechanism (direct fibrinolysis, PAI-1 inactivation, tPA upregulation)

What the evidence does not yet support with high certainty:

• Prevention of major cardiovascular events (no large Phase III RCT data)
• Treatment of diagnosed PAD or other structural arterial disease
• Replacement of anticoagulant medications in high-risk patients

A 2023 systematic review and meta-analysis published in Reviews in Cardiovascular Medicine noted that while fibrinolytic and antithrombotic effects of nattokinase across trials showed consistent trends, quantitative pooling was limited by data sparsity — reflecting the fact that the field is active and growing but not yet definitive on outcome-level endpoints. Research on the blood pressure side is covered in the dedicated nattokinase and blood pressure article.

For health-conscious adults seeking to support everyday circulation and vascular function, nattokinase offers a mechanistically coherent and well-tolerated option. For those managing cardiovascular diagnoses or taking blood thinners, physician consultation before use is necessary, not optional.

Who May Benefit — and Who Should Be Cautious

Based on the available evidence, nattokinase supplementation may be relevant for several adult populations interested in proactive vascular health support.

Potentially relevant for:

• Adults over 45 with age-related declines in natural fibrinolytic activity or elevated cardiovascular risk markers
• Those with occupational or lifestyle factors that reduce circulation — prolonged sitting, sedentary work, or limited physical activity
• People with cold extremities or poor peripheral circulation without an underlying diagnosed condition requiring prescription management
• Individuals seeking to complement lifestyle approaches to cardiovascular health — alongside exercise, diet, and stress management

Who should consult a physician first:

• Anyone currently taking anticoagulant or antiplatelet medications (warfarin, aspirin, NOACs, heparin). Nattokinase has fibrinolytic and antiplatelet properties; combining with prescription blood thinners may increase bleeding risk.
• Individuals with a history of bleeding disorders, recent surgery, or active cardiovascular conditions
• Pregnant or nursing women
• People scheduled for surgical procedures — nattokinase should typically be discontinued in advance

The real-world safety data from a study of vascular disease patients receiving 100 mg/2,000 FU nattokinase daily found the supplement was well-tolerated in controlled medical settings — but this study excluded patients with bleeding disorders and those already on anticoagulant therapy. The safety profile in that population is reassuring for the studied dose; caution is appropriate for populations outside the study criteria.

To understand nattokinase's connection to deep vein thrombosis specifically, the DVT article covers clinical evidence and risk context in more depth.

BioAbsorb Nattokinase: Formulated for Enzyme Delivery

For nattokinase to exert its fibrinolytic effects, it needs to survive the journey through the stomach — where the acidic environment can degrade enzymes before they reach the small intestine, where absorption occurs.

BioAbsorb Nattokinase Enzyme uses DRcaps delayed-release veggie capsules — a capsule technology designed to pass intact through stomach acid and release the enzyme in the small intestine. Unlike standard enteric-coated capsules that rely on phthalate-based coatings, DRcaps use a clean hypromellose formulation free of plasticizers.

Each capsule provides 100 mg of nattokinase standardised to 2,000 Fibrinolytic Units (FU) — the dose level used in the human studies demonstrating measurable fibrinolytic activity and improved peripheral blood flow in clinical research. Consistent potency at this level matters: too little activity and the enzyme may not reach the concentrations needed to shift the coagulation/fibrinolysis balance.

The formula is free of Vitamin K2 — an intentional design choice. Some nattokinase products combine with K2, which can be beneficial for bone health but introduces cardiovascular caveats for those already supplementing K2 elsewhere. The standalone formulation gives users flexibility over dosing without K2 accumulation concerns.

Additional formulation highlights:

• Non-GMO; manufactured in a Canadian GMP-certified facility
• Third-party tested for nattokinase activity (≥2,000 FU), heavy metals, gluten, and microbial contaminants
• Free of gluten, nuts, eggs, dairy, fish, shellfish, and all animal products — fully vegetarian
• 180-day supply at approximately $0.28/day — competitive cost per dose against comparable enzyme products

The protocol is simple: one capsule daily on an empty stomach. BioAbsorb Nutraceuticals publishes third-party testing documentation for each batch, providing the transparency that a health-conscious audience expects from an enzyme supplement.

Frequently Asked Questions

How does nattokinase actually improve circulation?

Nattokinase improves circulation through multiple pathways: it directly dissolves fibrin (the protein that forms clots and can narrow vessels), inactivates PAI-1 to amplify the body's own fibrinolytic system, stimulates tPA release from endothelial cells, and inhibits platelet aggregation. Research also shows it reduces red blood cell clumping and lowers blood viscosity at low flow rates — both factors that affect how smoothly blood moves through the smallest capillaries. Together, these mechanisms support more fluid blood flow at both the large-vessel and microvascular levels.

How long does it take for nattokinase to affect blood flow?

Human studies suggest measurable fibrinolytic activity begins within a few hours of a single oral dose. A crossover trial found elevated D-dimer (a fibrin degradation marker) at 6–8 hours post-dose, suggesting clot-dissolving activity was underway within the same day. Peripheral blood flow effects detected in the Watanabe study were observed following a single 2,000 FU dose. For longer-term circulatory changes — reduced arterial stiffness, sustained improvement in blood viscosity — consistent daily supplementation over weeks or months is more likely to produce meaningful results, though large long-term RCT data are still limited. For a broader look at nattokinase's long-term cardiovascular effects, see nattokinase for heart health.

Is nattokinase safe to take with blood pressure medication?

Some blood pressure medications — particularly ACE inhibitors — work through mechanisms that overlap with nattokinase's proposed effects. While there are no widely reported dangerous interactions with standard antihypertensives, adding a fibrinolytic supplement to a pharmacological regimen warrants physician oversight. The more important caution is with anticoagulants (warfarin, NOACs, heparin, aspirin at therapeutic doses), where nattokinase's blood-thinning effects could compound the drug's action and increase bleeding risk. Anyone on blood pressure or cardiovascular medications should discuss nattokinase with their prescribing physician before starting.

Does nattokinase help with cold hands and feet?

Cold extremities can result from multiple causes — poor peripheral circulation, Raynaud's syndrome, low blood pressure, or thyroid dysfunction — and nattokinase will not address all of them. However, the evidence base includes specific studies on peripheral blood flow: the Watanabe trial measured enhanced finger blood flow in healthy subjects, and a 2023 crossover study found faster skin temperature recovery after cold immersion following a single 2,000 FU dose, consistent with improved peripheral microvascular responsiveness. If cold hands and feet reflect poor microcirculation due to elevated blood viscosity or subtle fibrin accumulation, nattokinase may support improvement. Persistent symptoms warrant medical evaluation to rule out other causes.

Can nattokinase replace a blood thinner?

No — and this is an important distinction. Nattokinase has measurable fibrinolytic and antiplatelet properties, but it is not a pharmaceutical anticoagulant and has not been studied as a replacement for warfarin, NOACs, or other prescribed anticoagulant drugs in clinical populations. People taking these medications for conditions like atrial fibrillation, DVT, or post-surgical clot prevention should not substitute nattokinase without explicit guidance from their physician. Nattokinase may be appropriate as a proactive circulation support supplement for otherwise healthy adults, but it does not have the clinical evidence base to replace drugs prescribed for active coagulation disorders.

What dose of nattokinase is studied for blood flow effects?

The most consistently used dose in human studies examining nattokinase's circulatory effects is 2,000 Fibrinolytic Units (FU) per day — equivalent to the 100 mg capsule dose in most standardised commercial products. This was the dose used in the human fibrinolysis trial, the Watanabe peripheral blood flow study, and the 2023 skin temperature recovery crossover trial. Higher doses have been used in some trials (the ICC-PACS trial used 8,000 FU/day), but 2,000 FU is the most broadly studied and well-characterised dose for general circulatory support in healthy adults. Consult a healthcare provider to determine the appropriate dose for your individual situation.

Conclusion

Nattokinase works on blood flow through several distinct mechanisms — direct fibrin dissolution, PAI-1 inactivation, tPA upregulation, and platelet aggregation inhibition — and human trials confirm measurable fibrinolytic activity and improved peripheral blood flow signals at the standard 2,000 FU dose. In a world where peripheral artery disease affects over 200 million adults, and where microcirculation quietly deteriorates before symptoms appear, proactive vascular support has genuine relevance. If you're considering nattokinase for circulation, BioAbsorb Nattokinase Enzyme delivers the clinically studied 2,000 FU dose in a delayed-release DRcaps capsule — formulated to protect enzyme activity through stomach acid and deliver it where absorption happens.

Research References

1. Kurosawa Y, Nirengi S, Homma T, et al. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports. 2015;5:11601. Nature.com.
2. Jang JY, Kim TS, Cai J, Kim J, Kim Y, Shin K, et al. Nattokinase improves blood flow by inhibiting platelet aggregation and thrombus formation. Laboratory Animal Research. 2013;29(4):221–225. PubMed.
3. Pais E, Alexy T, Holsworth RE Jr, Meiselman HJ. Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clinical Hemorheology and Microcirculation. 2006;35(1-2):139–142. PubMed PMID: 16899918.
4. Nara N, Kurosawa Y, Fuse-Hamaoka S, Kuroiwa M, Endo T, Tanaka R, Kime R, Hamaoka T. A single dose of oral nattokinase accelerates skin temperature recovery after cold water immersion: A double-blind, placebo-controlled crossover study. Heliyon. 2023;9(7):e17951. PubMed PMID: 37483751.
5. Chen H, McGowan EM, Ren N, Lal S, Nassif N, Shad-Kaneez F, Qu X, Lin Y. Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases. Biomarker Insights. 2018;13:1178633718785130. Sage Journals.
6. Li X, Long J, Gao Q, Pan M, Wang J, Yang F, Zhang Y. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine. 2023;24(8):234. IMR Press.
7. Gallelli G, Di Mizio G, Palleria C, Siniscalchi A, Rubino P, Muraca L, et al. Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases. Nutrients. 2021;13(6):2031. PMC8231931.
8. Muric M, Nikolic M, Todorovic A, Jakovljevic V, Vucicevic K. Comparative Cardioprotective Effectiveness: NOACs vs. Nattokinase — Bridging Basic Research to Clinical Findings. Biomolecules. 2024;14(8):956. MDPI.
9. Hodis HN, Mack WJ, Meiselman HJ, Kalra VK, Liebman HA, Hwang-Levine J, et al. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical Hemorheology and Microcirculation. 2021;78(4):339–353. PubMed PMID: 33843667.
10. Criqui MH, Matsushita K, Aboyans V, et al. Epidemiology of Peripheral Artery Disease and Polyvascular Disease. Circulation Research. 2022;130(12):1818–1832. AHA Journals.
11. Zemaitis MR, Boll JM, Kato M, et al. Peripheral Arterial Disease. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan. NCBI Bookshelf.
12. Watanabe N, Takaoka S, Uehara S, Ohta M. Effect of nattokinase on the blood flow improvement in healthy subjects — a randomized, placebo-controlled, double-blind, cross-over study. Japanese Pharmacology and Therapeutics. 2018;46:1739–1748.
13. BioAbsorb Nutraceuticals. Official Website. bioabsorbnutraceuticals.com.
14. BioAbsorb Nutraceuticals. Nattokinase Enzyme — 100 mg / 2,000 FU / DRcaps / 180 Veggie Capsules. Product Page.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.